Researchers from Sungkyunkwan University and the Ulsan National Institute of Science and Technology (UNIST) have patented compounds reported to be useful for the treatment of Staphylococcus aureus infections.
Speaking at a Sept. 9 media briefing on the newly released Make America Healthy Again Strategy, U.S. Health and Human Services Secretary Robert Kennedy confirmed what could be the worst fears of many vaccine experts.
Researchers from the University of California, Davis have designed a novel gene therapy vector that selectively targets and kills cells infected with Kaposi’s sarcoma-associated herpesvirus (KSHV).
Epigenic Therapeutics Co. Ltd. closed a $60 million series B round to support clinical development of lead gene therapy candidates EPI-003 for chronic hepatitis B virus and EPI-001 for hypercholesterolemia.
Several South Korean biotech and biopharmaceutical companies completed IND submissions or won nods to start clinical trials in either the U.S. or South Korea, including SK Bioscience Co. Ltd., Genosco Inc., Pimedbio Inc., Sillajen Inc. and Ami Pharm Co. Ltd.
Speaking at a Sept. 9 media briefing on the newly released Make America Healthy Again Strategy, U.S. Health and Human Services Secretary Robert Kennedy confirmed what could be the worst fears of many vaccine experts.
Work at Blacksmith Medicines Inc. has led to the identification of new bacterial UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors reported to be useful for the treatment of Pseudomonas aeruginosa infection, lung diseases and infectious pneumonia.
Oregon Health & Science University and Washington University have jointly developed new tetrahydrobenzothiophene and tetrahydropyridothiophene derivatives reported to be useful for the treatment of flavivirus and alphavirus infections.
The envelope (E) proteins of Zika virus (ZIKV) and dengue virus (DENV) present a high degree of homology, which can lead to cross-reactive antibodies that exacerbate disease through antibody-dependent enhancement. This enormously challenges the development of effective ZIKV vaccines.
RSS
